Trial of Pembrolizumab for HIV-Positive Patients with Recurrent or Refractory Cancer
In this phase I clinical trial, HIV-positive patients receiving combination antiretroviral therapy who have cancer that has recurred after or has not responded to previous treatment will receive the immune checkpoint inhibitor pembrolizumab.
Media Type: Html
- SourceUrl: https://www.cancer.gov/node/1050232/syndication
- Syndication ID: 14598
- Language: English
- Source: National Cancer Institute (NCI)
- Date Syndication Captured: Friday, June 03, 2016 at 07:39 AM
- Date Syndication Updated: Monday, August 05, 2019 at 07:39 PM
Embed Code Snippet
To get the embed code snippet please Login.
